Hypofractionated Radiotherapy for Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT00214123
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 79
- Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy
- Prior bleomycin or gemcitabine chemotherapy
- Prior thoracic radiotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Grade 3 pneumonitis lasting greater than 2 weeks 90 days post radiotherapy (XRT)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
University of Wisconsin Hospital and Clinics🇺🇸Madison, Wisconsin, United States